PALONOSETRON injection, solution

Država: Sjedinjene Američke Države

Jezik: engleski

Izvor: NLM (National Library of Medicine)

Kupi sada

Preuzimanje Svojstava lijeka (SPC)
23-01-2020

Aktivni sastojci:

PALONOSETRON HYDROCHLORIDE (UNII: 23310D4I19) (PALONOSETRON - UNII:5D06587D6R)

Dostupno od:

Fresenius Kabi USA, LLC

INN (International ime):

PALONOSETRON HYDROCHLORIDE

Sastav:

PALONOSETRON 0.25 mg in 5 mL

Administracija rute:

INTRAVENOUS

Tip recepta:

PRESCRIPTION DRUG

Terapijske indikacije:

Palonosetron Hydrochloride (HCl) Injection is indicated for: •    Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses •    Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses Palonosetron HCl Injection is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.  Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.  In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron HCl Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.  Palonosetron HCl Injection is contraindicated in patients known to have hypersensitivity to the drug or any of its compon

Proizvod sažetak:

How Supplied Palonosetron Hydrochloride Injection is clear and colorless and is supplied in single-dose vials and pre-filled syringe as follows: NDC Number        Strength                                                      Package 63323-942-05        0.25 mg per 5 mL (0.05 mg per mL)         10 vials per carton 63323-942-42        0.25 mg per 5 mL (0.05 mg per mL)         1 pre-filled syringe per carton 63323-942-90        0.25 mg per 5 mL (0.05 mg per mL)         10 pre-filled syringes per carton Storage •  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. •  Protect from freezing. •  Protect from light.

Status autorizacije:

New Drug Application

Svojstava lijeka

                                PALONOSETRON - PALONOSETRON INJECTION, SOLUTION
FRESENIUS KABI USA, LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
PALONOSETRON HYDROCHLORIDE
INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
PALONOSETRON HYDROCHLORIDE
INJECTION.
PALONOSETRON HYDROCHLORIDE INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 2003
INDICATIONS AND USAGE
Palonosetron Hydrochloride (HCl) Injection is a serotonin-3 (5-HT )
receptor antagonist indicated in adults for:
• Moderately emetogenic cancer chemotherapy -- prevention of acute
and delayed nausea and vomiting associated with
initial and repeat courses. (1.1)
• Highly emetogenic cancer chemotherapy -- prevention of acute
nausea and vomiting associated with initial and repeat
courses. (1.1)
• Prevention of postoperative nausea and vomiting (PONV) for up to
24 hours following surgery. Efficacy beyond 24
hours has not been demonstrated. (1.2)
DOSAGE AND ADMINISTRATION
Chemotherapy-Induced Nausea and Vomiting
• The recommended adult dosage is 0.25 mg as a single intravenous
dose administered over 30 seconds. Dosing should
occur approximately 30 minutes before the start of chemotherapy. (2.1)
Postoperative Nausea and Vomiting
• The recommended adult dosage is 0.075 mg as a single intravenous
dose administered over 10 seconds immediately
before the induction of anesthesia. (2.1)
Instructions for Administration
• For a dose of 0.25 mg, use the entire contents (5 mL) of the
pre-filled syringe. Do not use the pre-filled syringe to
administer a dose less than 0.25 mg. Use the single-dose vial to
administer a dose of 0.075 mg. (2.2)
DOSAGE FORMS AND STRENGTHS
Injection: 0.25 mg palonosetron in 5 mL (0.05 mg/mL) in a single-dose
vial or a pre-filled syringe. (3)
CONTRAINDICATIONS
Hypersensitivity to the drug or any of its components. (4)
WARNINGS AND PRECAUTIONS
• Hypersensitivity reactions, including anaphylaxis, have been
reported with or without known hypersensitivity to other
select
                                
                                Pročitajte cijeli dokument
                                
                            

Upozorenja za pretraživanje vezana za ovaj proizvod